Our proprietary technology platform systematically leverages the powerful tools of big genomic data and AI to build molecular networks: a set of interconnected potential therapeutic targets.
Harnessing disease molecular networks, we screen both generic compounds and NCEs to develop novel drug combinations hitting multiple highly relevant disease targets.
Formulated with optimal doses of their components, our products are expected to be safer and more effective than existing therapies.
Find here the recording of the webcast during which our CEO and CMO presented and discussed the results of an interim analysis of our PXT3003 open-label Phase III Extension study
Pharnext will attend the 16th International Congress on Neuromuscular Diseases, wich is going virtual over two weekends: 21-22 and 28-29 May
Pharnext will attend the 2021 Annual Meeting of the Peripheral Nerve Society which is going virtual over two weekends in June: 12–13 and 25–27
Pharnext will attend the 24th Neuromuscular Days in Marseille, France